Smart inhaler company Adherium announced last week that it has received 510(k) clearance for over-the-counter sales of its inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler, called ...

About 69% of hospitalized COPD patients misused inhalers, 66% made critical errors during inhaler use, and 14% had insufficient PIF. An average of 1.4 and 1.3 and critical errors for every inhaler ...

The FDA approved the generic version, Wixela Inhub (fluticasone-salmeterol; Viatris), as the first generic maintenance inhaler for asthma and chronic obstructive pulmonary disease (COPD) in 2019 ...

That spurred three of the four leading inhaler companies (GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim) to announce in March 2024, that they would cap out-of-pocket costs at $35 per inhaler.

Summary. Primatene Mist inhalers provide temporary relief from mild, intermittent asthma symptoms. They are the only OTC asthma inhaler approved by the FDA to relieve asthma symptoms like wheezing ...

The researchers found that the incidence of a first moderate or severe COPD exacerbation was higher in patients who received budesonide-glycopyrrolate-formoterol (hazard ratio [HR], 1.09; [95% CI ...

Baldomero AK, Kunisaki KM, Wendt CH, et al. Guideline-discordant inhaler regimens after COPD hospitalization: associations with rurality, drive time to care, and fragmented care - a United States ...

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with ...

Surya Bhatt, M.D., MSPH Surya Bhatt, M.D., MSPH, professor of medicine in the Division of Pulmonary, Allergy, & Critical Care Medicine, is the latest winner of the Heersink School of Medicine's ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Thomas, Liji. (2024, August 25). Widespread inhaler misuse in COPD patients: Need for training.